Why the study?
Does non-pegylated liposomal doxorubicin reduce cardiotoxicity while maintaining anti-cancer efficacy compared to non-liposomal anthracyclines in patients with metastatic breast cancer?
Population
Patients with metastatic breast cancer (MBC)
Comparison
Non-pegylated liposomal doxorubicin, alone or in… vs Non-liposomal anthracyclines
Design
Review
Authors
Loading...
May support liposomal doxorubicin for improved therapeutic index in breast cancer; leaves open confirmation in randomized trials.
Does non-pegylated liposomal doxorubicin reduce cardiotoxicity while maintaining anti-cancer efficacy compared to non-liposomal anthracyclines in patients with metastatic breast cancer?
Non-pegylated liposomal doxorubicin offers a better therapeutic index than non-liposomal anthracyclines by reducing cardiotoxicity while maintaining anti-cancer efficacy.
Leonard et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: